SAN FRANCISCO -- Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

The cancellation of USAID contracts has threatened critical global health research. Plus, new guidance to prevent HIV in ...

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

The National Agency for the Control of AIDS has described information in sections of the media regarding the withdrawal of ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.